963-RAS(ON)抑制剂在胆管癌中的抗肿瘤活性与耐药机制 episode artwork

EPISODE · May 13, 2026 · 15 MIN

963-RAS(ON)抑制剂在胆管癌中的抗肿瘤活性与耐药机制

from 聊聊Sci

这份研究阐述了 RAS(ON) 多选择性抑制剂在治疗 KRAS 突变型胆管癌(CCA) 中的显著潜力。通过对人类和动物模型的广泛实验,研究团队证实了这种新药不仅能有效遏制肿瘤生长,还能通过与标准放化疗方案联用产生更强的协同杀伤作用。该文章详细剖析了胆管癌对 RAS 信号通路的生理依赖,并揭示了包括 KRAS 基因扩增和 MYC 过表达在内的多种耐药机制。研究特别强调,这种抑制剂作为单药或联合疗法,有望为这种难治性恶性肿瘤提供全新的临床治疗方案。此外,初步的临床数据也证实了受试患者对该疗法产生的积极缓解反应。总之,这组资料为推动靶向 RAS 治疗进入胆管癌临床实践奠定了坚实的科学基础。References:Entrialgo-Cadierno R, Morali K, Feliu I, et al. Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma[J]. Cancer Cell, 2026.前往小宇宙评论区与主播互动

Episode metadata supplied by the publisher feed · Published May 13, 2026

Embed this episode

Ready to play

963-RAS(ON)抑制剂在胆管癌中的抗肿瘤活性与耐药机制

0:00 15:30

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of 聊聊Sci?

This episode is 15 minutes long.

When was this 聊聊Sci episode published?

This episode was published on May 13, 2026.

Can I download this 聊聊Sci episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!